Table 4.

Grade 3 or greater‐non‐hematological adverse events

Arm	Patient	Serious adverse event †	Grade ‡	Onset timing	Relating drug (causative)
Arm C (n = 32)	#04	Hyperglycemia	3	6th cycle (day 4)	CHOP (diabetes)
	#07	Hyperglycemia	3	4th cycle (day 2)	CHOP, rituximab
	#13	Hypertension	3	1st cycle (day 3)	CHOP, rituximab
	#21	Total bilirubin elevation	3	2nd cycle (day 5)	– (constitutional)
	#23	Abdominal pain	3	1st cycle (day 9)	CHOP, rituximab
	#58	Acute cholangitis with elevated AST and ALT	3	3rd cycle (day 10)	CHOP, rituximab
	#59	Hyperglycemia, hypertension	3	5th cycle (day 6)	CHOP, rituximab
Arm S (n = 33)	#25	Total bilirubin elevation	3	6th cycle (day 132)	– (constitutional)
	#56	Diarrhea	4	1st cycle (day 13)	– (alimentary)
		Febrile neutropenia	3	3rd cycle (day 12)	CHOP
		Interstitial pneumonia	3	3rd cycle (day 15)	CHOP
	#62	Total bilirubin elevation	3	4th cycle (day 7)	CHOP
	#69	AST and ALT elevation	3	1st cycle (day 10)	CHOP
				2nd cycle (day 8)	CHOP
				6th cycle (day 29)	CHOP

^† Grade 3 or greater adverse events other than hematological toxicities that were observed during the treatment and follow‐up period (for 6 months after the last cycle of CHOP for Arm C, and for 4 months after the last rituximab infusion for Arm S).

^{‡ ‡} JCOG Toxicity Criteria, an expanded version of the NCI‐CTC, version 1.0.